MAPK pathway inhibitors have been shown to re-induce iodide uptake in RAI-refractory thyroid tumors in some patients, but not in others [21,22], suggesting that simultaneous or compensatory mechanisms might be involved in NIS regulation. The gene discussed is SLC5A5; the disease is thyroid tumor.